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Persistent cervical infections by approximately 15 carcinogenic genotypes of human papillomavirus (HPV)
cause virtually all cases of cervical cancer and its immediate precancerous precursor, cervical intraepithelial
neoplasia grade 3 or carcinoma in situ. As is shown in a meta-analysis by Koshiol et al. (Am J Epidemiol
2008;168:123–137), detection of carcinogenic HPV viral persistence could be used to identify women at the greatest
risk of cervical precancer. Speciﬁcally, women who have carcinogenic HPV infection that persists for at least 1 year
versus those whose infections clear are at signiﬁcantly elevated risk of having or developing cervical precancer.
However, before detection of HPV persistence can be used in cervical cancer screening, several considerations
need to be addressed: 1) validation and Food and Drug Administration approval of a reliable HPV genotyping test,
2) rational clinical algorithms based on risk of precancer and cancer for the clinical management of HPV persis-
tence, 3) clinician and patient acceptability of monitoring of HPV infections (including not responding excessively to
the ﬁrst positive HPV test andwaiting 1–2years for infections to either persist or resolve), and 4) patient compliance
with recommended follow-up. Investigators will need to address these and other key issues in order to realize the
potential utility of HPV viral monitoring for improving the accuracy of cervical cancer screening.
human papillomavirus 16; human papillomavirus 18; longitudinal studies; papillomavirus infections; uterine
cervical neoplasms
Abbreviations: CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial
lesions.
Based on the central role of persistent carcinogenic human
papillomavirus (HPV) in cervical carcinogenesis, testing for
carcinogenic HPV was recently introduced into cervical can-
cer screening (1). (Note that in this context, ‘‘HPV testing’’
alwaysreferstothe detectionofcarcinogenicHPVgenotypes
only; testing for noncarcinogenic HPV genotypes has no
clinical utility.) HPV testing has proven greater sensitivity
than cytologic screening (Papanicolaou smears) for detection
of cervical precancer (cervical intraepithelial neoplasia grade
3( C I N 3 ) )a n dc e r v i c a lc a n c e r( >CIN3) (2–6) and greater
reliability (7, 8). HPV testing is now commonly used in the
UnitedStatesto triage equivocal cytologic ﬁndings for colpo-
scopic referral. Co-testing with HPV and cytology is also
approved for primary (routine) cervical cancer screening of
women aged 30 years or more (9). Women aged 30 years or
older who test HPV- and cytology-negative are at extremely
low risk of incipient precancer and cancer (CIN3) over
periods of 10 years or more (10, 11). Therefore, screening
intervals in these women can be extended to 3 years in the
United States to make co-testing cost-effective (12).
Use of HPV testing in primary screening is only recom-
mended for women aged 30 years or older, because these
women are typically past the peak age of self-limited infec-
tions, which are very common in young women (13, 14).
Thus, the positive predictive value of CIN3 is higher in
women aged 30 years or more than in younger women (15,
Correspondence to Dr. Philip E. Castle, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd.,
EPS Room 5004, MSC 7234, Bethesda, MD 20892-7234 (e-mail: castlep@mail.nih.gov).
138 Am J Epidemiol 2008;168:138–144
American Journal of Epidemiology
ª 2008 The Authors
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License
(http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Vol. 168, No. 2
DOI: 10.1093/aje/kwn037
Advance Access publication May 15, 200816). In general, concurrently performed cytologic screening
adds little to the sensitivity and negative predictive value of
HPV testing (e.g., sensitivity of 97.4 percent for HPV test-
ing alone vs. 100 percent for HPV testing and Pap smears
using a threshold of atypical squamous cells of undeter-
mined signiﬁcance or worse (3)). In a publication based
on a meeting of experts, the International Agency for
Research on Cancer recently concluded that HPV testing
is an acceptable alternative to Pap smears/cervical cytology
for cervical cancer screening (17). However, despite its
greater sensitivity and overall accuracy, the enthusiasm for
using HPV testing in primary screening has been tempered
by its somewhat poorer positive predictive value in compar-
ison with cytologic analysis (e.g.,7.0 percent for HPV testing
vs. 8.7 percent for Pap smears, using a threshold of atypical
squamous cells of undetermined signiﬁcance or worse (3)).
Even at older ages, the prevalence of self-limited infection
can reach 10 percent (vs. approximately 5 percent for cer-
vical cytology), with only a minority of these women being
at risk of CIN3. Aviable strategy for managing the cases of
HPV-positive women, speciﬁcally identifying the subset
of women at risk of CIN3, would accelerate the adoption
of HPV testing into primary cervical cancer screening.
Several solutions have been suggested. One is to use cy-
tology as a reﬂex test for HPV-positive women, because it is
more speciﬁc for CIN3 (18), but the morphologic criteria
for the threshold of positive (abnormal) cytology would
need to be adapted (if possible) to avoid losses of sensitivity,
as observed by Mayrand et al. (3) using current criteria.
Another possibility is HPV genotyping that could target
the most carcinogenic of approximately 15 carcinogenic
genotypes and could permit the tracking of viral persistence.
Already, there is evidence that separate detection of HPV16
and HPV18 in cytologically normal women aged 30 years or
more might be a useful risk ‘‘stratiﬁer’’ (9, 19). Those
women who test positive for HPV16 or HPV18 might ben-
eﬁt from immediate colposcopy, while those who test neg-
ative for both could wait a year before being rescreened (9,
19). Given the fundamental role of persistent HPV in cervi-
cal carcinogenesis, its reliable measurement could increase
the accuracy of cervical cancer screening, by aiding in fur-
ther distinguishing HPV infections that pose a risk from
those which resolve on their own.
Koshiol et al. (20) conducted a systematic review and
meta-analysis of the relation betweendetection of HPV viral
persistence and the risk of precancerous lesions, deﬁned in
their analysis as histologic CIN2/3 or cytologic high-grade
squamous intraepithelial lesions (HSIL). Their key ﬁndings
regarding HPV persistencewere: 1) it was strongly linked to
the detection of precancer; 2) it was more strongly linked
with precancer and cancer than with equivocal or low-grade
lesions; 3) it was less strongly linked to precancer when
women with transient infection were used as a referent
group (i.e., women who were HPV-positive at the indicator
visit but were negative at a subsequent follow-up visit) than
when other referent groups were used (e.g., mixed HPV-
positive and -negative or HPV-negative women alone);
4) longer persistence, as detected by absolute duration or the
time interval between measurements, was more strongly
linkedtoprecancerandcancer;and5)HPVgenotype-speciﬁc
persistencewas no more related to risk of precancer than was
repeatedly testing positive for HPVin the aggregate.
Withsuchaheterogeneoussetofstudiesemployingdiffer-
ent tools, epidemiologic study designs, and limited numbers
of outcomes, Koshiol et al.’s analysis naturally had several
limitations. Most notable was the use of different endpoints;
some studies used histologic endpoints that included CIN2,
while other studies used cytologic HSIL to deﬁne disease.
CIN2 is the standard clinical threshold for treatment, but
not all CIN2 is cervical precancer. The CIN2 diagnostic cat-
egorycanincludewomen with nothing more than acuteHPV
infections, including those caused by noncarcinogenic HPV
(21). HSIL cytology is generally a speciﬁc but insensitive
cytologicindicatorofcervicalprecancer.Inaddition,wemust
acknowledgethatcolposcopy,visualizationofthecervix,and
diagnostic biopsy are insensitive for the detection of cervical
precancer(22–24),especiallyinwell-screenedpopulationsin
which most large and obvious precancerous lesions have al-
ready been detected and treated. Therefore, viral persistence
may reﬂect a concurrent, visually unapparent precancerous
lesion as well as indicate those women at risk for developing
precancer. All of these limitations probably resulted in un-
derestimationofriskrelationsintheanalysisbyKoshioletal.
While monitoring of HPV infections for persistence ver-
sus clearance provides excellent risk stratiﬁcation in study
cohorts, it isfair to ask is whether its use is currently feasible
in realistic cervical cancer screening programs.
Is the relation between HPV persistence (vs. transience)
and risk of CIN3 sufﬁciently robust to be clinically
useful?
In the paper by Koshiol et al. (20), the summary-estimate
relative risk for cervical precancer for any persistent versus
transient HPV infection was 14.7 (range, 5.4–119.1). Using
the benchmarks of odds ratios/relative risks of approximately
20–25 or greater for a clinically useful biomarker established
by Pepe et al. (25), considering any viral persistence may be
insufﬁcient for clinical use. However, with data restricted to
those studies that examined the risk for persistence of 1 year
or more, the summary-estimate relative risk increased to
42.9, suggesting that monitoring of HPV viral persistence
for at least 1 year might be useful in patient management.
There is some evidence to support a minimum 1-year
threshold for clinically meaningful persistence (26). At least
50 percent of all HPVinfections clear within 1 year (27–29).
Follow-up studies with repeat measurements taken over
a period of 1 year (30) or 2 years (11) begin to distinguish
infections and associated lesions that pose greater risk from
those posing lower risk. Women with 1-year HPV genotype-
speciﬁc persistence remain at elevated risk of cervical
precancer and cancer (24 percent for CIN2 or worse and
15 percent for CIN3 or worse) for several years after an
index colposcopic evaluation has failed to detect disease (4).
What is the appropriate clinical response to detection
of HPV persistence or clearance?
The objective of any test, including monitoring of HPV
infections, is to identify women at greater or lesser risk,
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new risk stratiﬁcation tools like HPV genotyping and mon-
itoring of HPV infections become available, the clinical re-
sponse to a positive or negative result (for example,
persistence vs. transient infection) should be predicated on
and standardized to previous established management
guidelines for that risk level. While professional clinical
societies and cancer prevention experts will need to estab-
lish the thresholds of risk and the appropriate clinical re-
sponses, current clinical algorithms based on cytology and
colposcopy, such as those recommended by the American
Society for Colposcopy and Cervical Pathology (9, 32), can
provide some guidance for risk-based algorithms (31). For
example, women with a <2 percent risk of cervical pre-
cancerandcanceroveratypicalscreeninginterval(1–3years)
(e.g., negative cytology and HPV-negative equivocal cytol-
ogy) can be sufﬁciently reassured that a return to routine
screening is acceptable. Risks of 2–<10 percent (e.g., colpo-
scopy and CIN1 biopsy) warrant increased surveillance. A
10 percent risk of CIN3, like low-grade squamous intra-
epithelial lesion cytology (9), should merit colposcopy. By
analogy, women with at least 1-year HPV persistence prob-
ablymeritcolposcopyforaslongastheinfectionpersists(4).
New risk-stratiﬁcation tools like HPV testing and HPV
genotyping should be considered in their totality, without
‘‘cherry-picking’’ of particularly palatable parts. For exam-
ple, the addition of HPV testing for triage of equivocal
cytology was accepted quickly in that HPV-positive women
are sent immediately to colposcopy. There has been more
reluctance to treat HPV-negative women with equivocal cy-
tology as negative and safe (9), despite the proven low risk
in these women (33). For monitoring of HPV persistence,
even greater potential for misuse exists. If there is an unwill-
ingness to manage less aggressively those women without
HPV persistence, strategies for monitoring HPV infections
willproducemainlyincreasedcostsandexcessivetreatment,
whichnegativelyaffectsreproductiveoutcomes(34).Misuse
of HPV testing has already been reported (35, 36), and in-
troduction of HPV genotyping for viral monitoring into
clinical practice could exacerbate the situation.
How could detection of HPV viral persistence be
incorporated into clinical practice?
Based on a risk model, several possible algorithms could
be considered, and one based on HPVas the primary screen-
ing test is presented in ﬁgure 1. Women who tested negative
for HPV would be reassured against cervical cancer and
would not need to undergo the next round of screening for
3–5 years. Women who tested positive for HPVeither would
be managed according to the HPV genotype(s) detected, if
an HPV genotyping test was used as the primary test, or their
residual specimen would be reﬂex-tested for the HPV geno-
type(s) present. Women who tested positive for carcinogenic
HPV genotypes other than HPV16 and HPV18 would return
in 1 year and be retested, with persistence triggering referral
to colposcopy. Cytologic analysis might also be conducted as
an adjunct for increased safety if a woman’s past history was
unknown (e.g., if she had joined a new health plan and her
screening history was unavailable) and subsequently phased
out as future risk was determined through monitoring of the
outcome of new HPV infections.
Because improved accuracy in screening may also be
accompanied by greater complexity, with increasing num-
bers of combinations of test results, simpliﬁed reporting of
results by grouping of those results that represented similar
risks and would be managed identically might be useful.
That is, it might be sufﬁcient to report ‘‘persistent carcino-
genic HPV’’ for 1-year persistence of carcinogenic geno-
types other than HPV16 and HPV18 (and perhaps HPV45)
rather than reporting persistent HPV31, HPV35, or HPV58,
as their risks are similar. The development and use of a risk
calculator, a nomogram, that included important modiﬁers
of risk and management recommendations from profes-
sional clinical societies like the American Society for Col-
poscopy and Cervical Pathology might be helpful.
What are some of the practical considerations involved
in monitoring HPV infections for persistence or
clearance?
Monitoring of HPVinfections for persistence or clearance
involves several practical considerations. First, well-
validated tests must be available. Currently, there are no
tests for HPV genotyping with Food and Drug Administra-
tion approval, which is required for their use in cervical
cancer screening and serves as a benchmark for validation
(37). Second, measurement of viral persistence must be
cost-effective. The objective of measuring viral persistence,
as we discussed above, is to stratify risks and match the
appropriate and established clinical care to the risk. Specif-
ically, unless a new strategy leads to a ‘‘sliding scale’’ for
the intensity of clinical management (from extended screen-
ing intervals for the lowest risk to colposcopy and treatment
for the highest risk) based on population risk, HPV genotyp-
ing will only increase the costs of screening without patient
beneﬁt. Third, and related to cost, the use of HPV genotyp-
ing implies both clinician and patient acceptability. Clini-
cians must be willing to recommend and follow through
with the appropriate management based on the risk linked
to the outcome. For example, doctors and patients must be
willing to wait for a year or two following a positive HPV
test to determine whether the infection will persist or re-
solve. Fourth, detection of HPV viral persistence not only
requires acceptance, it requires compliance with follow-up;
that is, viral monitoring may not be applicable to popula-
tions of women with poor follow-up.
In addition to irregularities of routine screening or poor
compliance with recommendations, women may move or
switch medical programs or primary clinicians. In many cir-
cumstances, data on clinical history and test results are not
linked. Therefore, given an HPV-positive test result, clini-
cianswillbeuncertainastohowlongthepatienthasharbored
the infection. Again, cytology screening may be a useful
addition when the patient’s history is unknown (ﬁgure 1).
Do we need to detect all HPV genotypes individually?
One of the more intriguing ﬁndings by Koshiol et al. (20)
was that measurement of HPV genotype-speciﬁc viral
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repeated positive testing for any carcinogenic HPV geno-
type without discrimination as to which HPV genotype(s)
was present. Kjaer et al. (11) demonstrated that testing for
any carcinogenic HPV genotype twice over a 2-year interval
effectively stratiﬁed cytologically negative women into
higher-risk (positive/positive), medium-risk (positive/nega-
tive or negative/positive), and lower-risk (negative/negative)
populations over an 11-year follow-up period (ﬁgure 2). It
may therefore be sufﬁcient for clinical applications to in-
dividually detect the most risky HPV genotypes like HPV16
and HPV18, for which there is some evidence (19) of utility,
and detect the remaining HPV genotypes in aggregate rather
than individually (i.e., repeatedly testing positive for any
other carcinogenic HPV vs. carcinogenic HPV genotype-
speciﬁc persistence). This would simplify communication
of test results from clinical laboratories to clinicians while
potentially providing robust risk stratiﬁcation. More data are
needed to examine the best format (partial vs. complete
HPV genotyping) for clinical applications.
One caveat is that many of these data were based on
earlier, research-oriented HPV genotyping tests that may
not be as analytically sensitive as current, commercialized
HPV genotyping tests (38). Nevertheless, it might be in-
ferred from these data that HPV genotyping systems may
not be sufﬁciently robust to identify women with persistent
HPV infections more accurately than the Food and Drug
Administration-approved test (the Hybrid Capture 2 assay
(Digene Corporation, Gaithersburg, Maryland)), which de-
tects all carcinogenic genotypes as a pool. Most current
HPV genotyping assays rely on polymerase chain reaction
ampliﬁcation of a 60- to 450-base-pair region of the HPV L1
gene using consensus primers (i.e., targeting conserved re-
gions of the gene). However, a transient coinfection of any
HPV genotype, carcinogenic or not, can compete for poly-
merase chain reaction primers (39) and cause a false-negative
test for the clinically relevant genotype. Of the current HPV
genotyping systems being developed and commercialized,
there are no data on their reliability to repeatedly mea-
sure individual genotypes over time to establish risk of
FIGURE 1. A proposed clinical algorithm for using carcinogenic human papillomavirus (HPV) testing as the primary screening test and HPV
genotyping to triage carcinogenic HPV-positive results and monitor viral persistence as a risk factor for cervical precancer and cancer. If the
molecular HPV test used for screening (e.g., Hybrid Capture 2 (Digene Corporation, Gaithersburg, Maryland)) does not provide information on the
individual HPV genotype(s) present, only on whether a woman is or is not positive for carcinogenic HPV, a second test would be necessary to
determine which HPV genotype(s) are present. Cytologic analysis may be a useful adjunct for women whose screening history is unknown, with
women having cytologically detected high-grade squamous intraepithelial lesions (HSIL) being referred to colposcopy immediately. Depending on
the exact format of the HPV testing (full or partial HPV genotyping), the most robust use of HPV genotyping, and the associated risks of cervical
intraepithelial neoplasia grade 3 or cervical cancer (CIN3), women who repeatedly test positive for the other carcinogenic HPV genotypes
(individually or in aggregate) may need increased surveillance or colposcopy (31). Following a carcinogenic HPV-negative test, women may be
rescreened at an extended interval of 3 or more years, depending on the acceptable risk of CIN3 (and, more speciﬁcally, the reassurance against
cancer), which may depend on the previous test results.
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will need to be established to assess the possibility of track-
ing approximately all 15 individual carcinogenic HPV in-
fections for clinical management. Alternatively, limiting the
detection of individual HPV genotypes to the most risky
(e.g., HPV16 and HPV18) may provide the best compro-
mise for clinical use, relying on repeated positive testing for
the pool of less risky HPV genotypes as an indicator of
persistent infection.
What additional questions need to be addressed?
Some additional questions need to be addressed. First,
a key clinical question is how long to follow women with
HPV infections. Koshiol et al. (20) stratiﬁed the risk on
measured HPV persistence of less than 12 months versus
12 or more months. It would be useful to explore more ﬁnely
the relation between duration of persistence and risk of cer-
vical precancer and cancer. Longer-enduring infections will
be more strongly linked to the risk of CIN3, but any gain
in positive predictive value obtained by monitoring HPV
infections longer must be weighed against any decreased
reassurance against cancer developing while waiting for
transient infections to clear. Second, age is likely to be an
important modiﬁer of risk, and at what age might HPV viral
monitoring be useful? The cutoff age of 30 years for HPV
testing was chosen as a surrogate for viral persistence; that
is, a greater proportion of women who are aged 30 years or
older are past the age peak of self-limited infections, and
when they test HPV-positive they are more likely to have
worrisome, persistent HPVinfections than arewomen youn-
ger than 30. It is possible that more accurate identiﬁcation of
women with HPV persistence will permit HPV viral moni-
toring in younger women (ages 25–29 years) in order to ﬁnd
early precancerous lesions, as long as the clinical response
upon ﬁrst detection of HPV is not excessive.
Third, more data are needed on the persistence of individ-
ual HPV genotypes and the risk of precancer. In particular, it
would be useful to know how the risks for persistent HPV16
and HPV18 infections differ from those for other HPV geno-
types, given that HPV16 and HPV18 are the most carcino-
genic HPV genotypes. Certainly, there is evidence that
persistence of HPV16 is highly linked to the risk of CIN3
(40). There is no epidemiologic evidence that HPV18 per-
sistence is more tightly linked to the development of CIN3
than persistence of other HPV genotypes, but this may be
the consequence of underdetection of HPV18-induced cer-
vical precancer (41–43). It would additionally be useful to
evaluate the risk for non-HPV16/HPV18 genotypes, since
vaccination against HPV16 and HPV18 (44, 45) may elim-
inate these infections from some populations. Finally, there
are important new data on the difference between preva-
lently detected and incidently detected HPV infections. As
already discussed, prevalently detected HPV infections are
‘‘left-censored’’; that is, there is an unknown duration of
infection prior to detection, and there is evidence (27) that
the longer an infection endures, the more likely it will con-
tinue to do so. This relation naturally leads to an age effect
in which there is a greater likelihood of persistence of prev-
alently detected HPV infections with increasing age at ﬁrst
detection (46). As HPV screening programs mature, infec-
tions will increasingly be found as incident infections during
longitudinal follow-up. The relation between HPV persis-
tence and risk of CIN3, and the modiﬁers of that risk, will
likely differ substantially between prevalently detected and
incidently detected HPV infections because the length of
duration preceding detection—that is, ‘‘age of infec-
tion’’—will be substantially different.
In conclusion, the goal of adding new tests to successful
cervical cancer screening programs is to improve the accu-
racy of screening and thereby reduce overtreatment and
possibly increase cost-effectiveness. Monitoring of HPV in-
fections for cervical cancer screening is a potentially prom-
ising tool, but its use clinically awaits further evaluations to
determine the critical parameters and the availability of re-
liable, validated methods of detection. Koshiol et al. (20)
have provided an important analysis that highlights the pos-
sible utility of HPV viral monitoring while helping to iden-
tify gaps in knowledge. As discussed above, unresolved key
issues remain before HPV monitoring can be introduced
into clinical applications. More fundamentally, we do not
yet understand the biologic determinants of viral clearance
versus persistence. Identiﬁcation of biomarkers that strongly
predict viral persistence might overcome the aforemen-
tioned limitations of repeat measurements required to iden-
tify those women with persistent infections.
It is also unclear when persistent infections become pre-
cancerous lesions, that is, when detection of viral persis-
tence is synonymous with the presence of a precancerous
lesion. This transition will not be clariﬁed while the diag-
nostic procedure, colposcopy and directed biopsies, is only
moderately sensitive (22, 23). Women with persistent HPV
infection remain at high risk for CIN2 following a colpo-
scopic evaluation that is negative for CIN2 (4)—again
evidence for the insensitivity of and poor reassurance pro-
vided by the diagnostic procedure. As screening tools
FIGURE 2. Cumulative (absolute) risk of histologic cervical intra-
epithelial neoplasia grade 3 or cervical cancer (CIN3) over 11 years
of follow-up following the results of two carcinogenic human papillo-
mavirus tests conducted at a 2-year interval in women aged 20–29
years at baseline (adapted from Kjaer et al. (11)). The results are
stratiﬁed according to the paired results. The bracket indicates the
period of typical screening intervals.
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or will have cervical precancer will approach certainty and
will supersede the sensitivity of colposcopy. Without im-
provements in colposcopy (47), the distinctions made with
HPV genotyping and viral monitoring will be restricted by
the limitations in colposcopy, and clinicians, faced with un-
realistic medico-legal pressures to prevent all cancer, may
lose conﬁdence in its use.
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